Cargando…

Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis

Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ashim, Potty, Anish G., Maffulli, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308306/
https://www.ncbi.nlm.nih.gov/pubmed/37396144
http://dx.doi.org/10.3389/fpain.2023.1216190
_version_ 1785066217632956416
author Gupta, Ashim
Potty, Anish G.
Maffulli, Nicola
author_facet Gupta, Ashim
Potty, Anish G.
Maffulli, Nicola
author_sort Gupta, Ashim
collection PubMed
description Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and relies on the utilization of biologics including platelet-rich plasma (PRP). Several peer-reviewed studies have documented the safety and efficacy of autologous PRP in mitigating symptoms in knee and hip OA patients. Nonetheless, only few studies investigated the safety and efficacy of allogenic PRP. This mini review summarizes the outcomes of preclinical and clinical studies using allogenic PRP for treatment of knee or hip OA. We identified 3 preclinical and 1 clinical study using allogenic PRP for treatment of knee OA, and only 1 clinical study using allogenic PRP for treatment of hip OA. Administration of allogenic PRP is safe and probably efficacious in patients with knee or hip OA. However, more pre-clinical studies and high-powered, multi-center, non-randomized and randomized controlled trials with extended follow-up are warranted to further establish the safety and efficacy of allogenic PRP to justify its clinical use.
format Online
Article
Text
id pubmed-10308306
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103083062023-06-30 Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis Gupta, Ashim Potty, Anish G. Maffulli, Nicola Front Pain Res (Lausanne) Pain Research Osteoarthritis (OA) induces tremendous amounts of stress and financial burden on patients and healthcare systems worldwide. Current treatments have limitations and do not address the etiopathogenetic cause of OA. Regenerative medicine may circumvent limitations posed by traditional modalities and relies on the utilization of biologics including platelet-rich plasma (PRP). Several peer-reviewed studies have documented the safety and efficacy of autologous PRP in mitigating symptoms in knee and hip OA patients. Nonetheless, only few studies investigated the safety and efficacy of allogenic PRP. This mini review summarizes the outcomes of preclinical and clinical studies using allogenic PRP for treatment of knee or hip OA. We identified 3 preclinical and 1 clinical study using allogenic PRP for treatment of knee OA, and only 1 clinical study using allogenic PRP for treatment of hip OA. Administration of allogenic PRP is safe and probably efficacious in patients with knee or hip OA. However, more pre-clinical studies and high-powered, multi-center, non-randomized and randomized controlled trials with extended follow-up are warranted to further establish the safety and efficacy of allogenic PRP to justify its clinical use. Frontiers Media S.A. 2023-06-15 /pmc/articles/PMC10308306/ /pubmed/37396144 http://dx.doi.org/10.3389/fpain.2023.1216190 Text en © 2023 Gupta, Potty and Maffulli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pain Research
Gupta, Ashim
Potty, Anish G.
Maffulli, Nicola
Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title_full Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title_fullStr Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title_full_unstemmed Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title_short Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
title_sort allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis
topic Pain Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308306/
https://www.ncbi.nlm.nih.gov/pubmed/37396144
http://dx.doi.org/10.3389/fpain.2023.1216190
work_keys_str_mv AT guptaashim allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis
AT pottyanishg allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis
AT maffullinicola allogenicplateletrichplasmafortreatmentofkneeandhiposteoarthritis